Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Breanna Brousseau

Nurse Practitioner Wilmington, NC Medical Doctor

NPI 1578235453 CMS profile 11258725

1202 Medical Center Dr, Wilmington, NC 28401

Open in the dashboard

General payments

$12,261

372 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Breanna Brousseau of Wilmington, NC is reported in the CMS Open Payments database as having received $12,261 across 372 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,717 105
2024 General $3,356 105
2023 General $4,678 128
2022 General $1,511 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Breanna Brousseau
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Breanna Brousseau were reported at $2,717. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Breanna Brousseau Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $1,511 $152 $48–$470 $149
2023 $4,678 $166 $54–$529 $160
2024 $3,356 $173 $55–$556 $164
2025 $2,717 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $7,029 219 payments
  2. SI-BONE, Inc. $1,448 23 payments
  3. Relievant Medsystems, Inc. $918 8 payments
  4. AbbVie, Inc. $653 38 payments
  5. Globus Medical, Inc. $468 12 payments
  6. Medtronic, Inc. $351 11 payments
  7. Nevro Corp. $234 9 payments
  8. Amneal Pharmaceuticals LLC $153 11 payments
  9. Novo Nordisk Inc $136 3 payments
  10. Pfizer Inc. $133 7 payments
  11. Other $738 31 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $9,722 363 payments
  2. Travel and Lodging $2,539 9 payments
Products named General payments · program years 2022–2025
  1. WaveWriter Alpha Prime 16 $3,103 152 payments
  2. IFUSE IMPLANT SYSTEM $1,027 6 payments
  3. Intracept Pain $918 8 payments
  4. Intracept Pain $896 7 payments
  5. General - Pain Management $706 13 payments
  6. Senza $468 12 payments
  7. BOTOX $314 20 payments
  8. Superion Indirect Decompression System $293 7 payments
  9. INTELLIS ADAPTIVESTIM $246 7 payments
  10. QULIPTA $245 19 payments
  11. Other $2,218 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,209

Median for Nurse Practitioner: 389

Drug cost

$14,358

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Baclofen Generic 273 $3,838
Pregabalin Generic 189 $3,464
Gabapentin Generic 276 $3,124
Methocarbamol Generic 191 $1,515
Lidocaine Generic 12 $819
Tizanidine Hcl Generic 51 $508
Cyclobenzaprine Hcl Generic 70 $396
Meloxicam Generic 70 $348
Amitriptyline Hcl Generic 25 $177
Methylprednisolone Generic 32 $157

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$110,802

Of which drugs: $9,465

Medicare patients

506

Average age 73

Services billed

12,285

320 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Depression 32%
Chronic kidney disease 31%
Ischemic heart disease 29%
COPD 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 136 6,640 $669
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 166 2,155 $183
Injection, methylprednisolone acetate, 40 mg J1030 Office 43 43 $161

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $142
$142 — —
UBRELVY
  • AbbVie, Inc. $49
$49 — —
Xeomin
  • Merz Pharmaceuticals, LLC $40
$40 — —
HORIZANT
  • CutisPharma, Inc. $37
$37 — —
QULIPTA
  • AbbVie, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record